Tesamorelin Reduces Belly Fat and Liver Fat in HIV Patients: Meta-Analysis of Trials | Research

The takeaway

A meta-analysis of RCTs confirms tesamorelin, a GHRH analogue, significantly reduces visceral and hepatic fat in HIV-associated lipodystrophy with an acceptable safety profile.

Significant VAT and hepatic fat reduction
Tesamorelin vs. placebo across randomized trials in HIV lipodystrophy

What the researchers found

Tesamorelin significantly reduces visceral and hepatic fat in HIV-associated lipodystrophy versus placebo across randomized controlled trials.

Why it matters

HIV-associated lipodystrophy causes significant morbidity and cardiovascular risk. Tesamorelin provides targeted therapy for a condition with few effective treatments.

How the study worked

Systematic review and random-effects meta-analysis of RCTs evaluating tesamorelin vs. placebo in adults with HIV; PubMed, Embase, Scopus, Web of Science, CENTRAL searched through July 2025.

What this study cannot tell us

Limited number of available RCTs; mostly short to medium-term follow-up; HIV-specific population limits generalizability.

How to read the evidence

Meta-analysis of RCTs — strong evidence level for this specific population and outcome.

When this study was published

Published 2026 in Obesity Research & Clinical Practice. Searches through July 2025.

The bigger picture

As people with HIV live longer, managing metabolic complications like lipodystrophy becomes increasingly important for long-term health and quality of life.

Questions still open

What are the long-term effects of tesamorelin beyond trial durations?
Could tesamorelin benefit non-HIV lipodystrophy populations?

Common questions

What is HIV lipodystrophy?

It's a condition in HIV patients where fat accumulates in the belly and around organs (visceral fat) while being lost from the face and limbs. It increases cardiovascular risk and causes body image distress.

How does tesamorelin work?

Tesamorelin stimulates the body's own growth hormone release, which helps break down visceral (belly) fat and reduce liver fat accumulation.

Read the original research

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Obesity research & clinical practice, 20(1), 2-12

View on PubMed ↗Publisher’s paper ↗

Citation

Badran, Ahmed Samy; Helal, Abdulrhman; Shata, Karim Samir; Ayesh, Hazem. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.. Obesity research & clinical practice, 20(1), 2-12. https://doi.org/10.1016/j.orcp.2026.01.002